Kestra Reports Positive Real-World Study Results For ASSURE Wearable Defibrillator

Kestra Medical Technologies (KMTS) reported positive results from its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study included 21,612 patients and showed 100% shock conversion success. KMTS stock closed at $28.64, up 0.07%, with no after-hours movement.

Original reporting
Published Nov 16, 2026, 12:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Kestra Reports Positive Real-World Study Results For ASSURE Wearable Defibrillator — source image
Decision brief

The 30-second read

$KMTSBullishMed
01

Why it matters

The positive safety and efficacy outcomes could enhance the company's market positioning and support future sales growth.

02

Market read

First disclosure of pivotal post‑approval study data for a listed med‑tech firm, likely to influence investor sentiment.

03

What to watch

Potential regulatory scrutiny on the new algorithm's claims and insurance coverage decisions.

Relevance 8/10Novelty 8/10Timing: today

Background

Kestra Medical Technologies (KMTS) is a U.S. listed developer of wearable cardioverter defibrillators. The ACE‑PAS study was FDA‑required and spanned 2021‑2025.

Company-level read

Ticker impact

$KMTSBullishHigh confidence
Context

Kestra Medical Technologies disclosed positive post‑approval study results for its ASSURE wearable defibrillator, meeting safety and effectiveness goals.

Expected impact

likely upward pressure as investors price in improved safety profile and potential market adoption.

Evidence & confidence

First‑time disclosure of robust clinical data for a FDA‑required study; market typically reacts positively to such efficacy and safety improvements.

Market effects

May boost confidence in the wearable cardiac device sector and could spur competitor activity.

U.S. market focus as the study covered patients across 35 states.

Limited to companies with similar cardiac monitoring technologies.

Counterpoint

If reimbursement or adoption hurdles persist, the data may not translate into revenue growth.

Key entities

  • Kestra Medical Technologies

    Developer of the ASSURE wearable cardioverter defibrillator.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.